Endo Health Solutions said today it is acquiring Canadian-based specialty pharma company Paladin Labs for roughly $1.6 billion, in a stock and cash deal that expands the buyer’s global presence, ...

DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc.

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed ...

DUBLIN and LUGANO, Switzerland, July 31, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, are ...

Endo Health Solutions ($ENDP) needs a shot in the arm, now that its lead drug Lidoderm faces generic competition. And Endo may have found just that. The has company ...

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI ® (cenobamate tablets) is now available in Canada. XCOPRI is ...

Endo Health Solutions Inc. agreed to buy Canadian specialty-pharmaceutical company Paladin Labs Inc. for about $1.6 billion, allowing Endo to continue its transition into a specialty health-care ...

(Reuters) - Endo International Plc has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc , people familiar ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Strata Skin Sciences and Endo International are both ...

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its ...